Exai Bio, a next-generation oncRNA- and generative AI-based liquid biopsy company, today announced a peer-reviewed publication about its generative AI model in Nature Communications. The paper ...

OneCell Diagnostics has secured $16 million in a Series A round as it aims to limit cancer recurrence using AI advancements ...

The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung ...

Lung cancer treatment has witnessed a revolution in recent years, largely driven by the increasing understanding of genetics ...

FoundationOne Liquid CDx is now FDA-approved to identify mNSCLC patients with MET exon 14 skipping alterations for tepotinib ...

The Guildford, England-based liquid biopsy company is presenting the new test results at the American Association for Cancer Research's Special Conference, 'Liquid Biopsy: From Discovery to Clinical ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.

CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ...

Biofidelity, a leader in innovative genomic solutions, today announced the launch of Aspyre Lung Reagents (research use only) for liquid biopsy samples. Aspyre Lung identifies established non-small ...